Investor Presentation Q1-Q3 2020
51
Investor presentation
First nine months of 2020
SaxendaⓇ addresses a global unmet need for medical weight
management
Global obesity prevalence
SaxendaⓇ launched countries
Global reimbursement status
Novo NordiskⓇ
70% access in commercial channel, but due to
employer opt-in, effective access is around 20%
Reimbursement in IO is predominantly out-of-pocket
NICE has recommended SaxendaⓇ for use by
NHS in select patient populations
~60% coverage by private insurance, 20% of
which includes restricted/unrestricted coverage
SaxendaⓇ reimbursed April 2020 in selected
patient groups
<10% ●<10-19.9%
<20-29.9%
>30%
SaxendaⓇ now launched in 54 countries
+
NAO: North America Operations; IO: International Operations; EMEA: Europe, Middle East, Africa; RoW: Rest of World;
CER: Constant exchange ratesView entire presentation